VERA revenueQ3 2026$10.28M
VERA revenue was $10.28M in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier.
Vera Therapeutics Inc. (VERA) financials
For the twelve months ended Sep 30, 2026, Vera Therapeutics Inc. reported -$415.31M of net income.
- Net income, TTM
- -$415.31M
- Free cash flow, TTM
- -$376.05M
- EPS, diluted, TTM
- -$5.90
- Cash
- $55.32M
- Total debt
- $75.43M
- Market cap
- $2.15B
FY2020FY2025
FY2020FY2025
VERA revenue and earnings growth
VERA net incomeQ3 2026-$93.71M
VERA net income was -$93.71M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$80.29M a year earlier. For the full fiscal 2025 it was -$299.62M, compared with -$152.15M in fiscal 2024.
VERA EPSQ3 2026-$1.30
VERA diluted EPS was -$1.30 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.26 a year earlier. For the full fiscal 2025 it was -$4.66, compared with -$2.75 in fiscal 2024.
VERA free cash flowQ3 2026-$99.18M
VERA free cash flow was -$99.18M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$62.04M a year earlier. For the full fiscal 2025 it was -$241.73M, compared with -$135.65M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $215.26M | $126.17M | $78.22M | $68.99M | $22.48M | $45.21M |
| Selling, general and admin | $100.22M | $41.00M | $23.79M | $21.91M | $11.92M | $4.04M |
| Operating income | -$315.47M | -$167.17M | -$102.01M | -$90.90M | -$34.40M | -$52.24M |
| Interest expense | $7.53M | $7.63M | $3.79M | $992.0K | $20.0K | $166.0K |
| Pre-tax income | -$299.61M | -$152.15M | -$95.99M | -$89.06M | -$32.61M | -$53.41M |
| Income tax | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | -$1.0K |
| Net income | -$299.62M | -$152.15M | -$95.99M | -$89.06M | -$32.61M | -$53.41M |
| EPS, basic | -$4.66 | -$2.75 | -$2.25 | -$3.35 | -$2.43 | -$166.93 |
| EPS, diluted | -$4.66 | -$2.75 | -$2.25 | -$3.35 | -$2.43 | -$166.93 |
| Diluted shares | 64.2M | 55.3M | 42.7M | 26.6M | 13.4M | 319,963 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $354.73M | $92.65M | $45.68M | $43.75M | $79.97M | $54.00M |
| Short-term investments | $359.86M | $548.21M | $115.03M | $71.19M | $0 | - |
| Receivables | $0 | - | - | - | - | - |
| Inventory | $0 | - | - | - | - | - |
| Current assets | $728.88M | $651.22M | $172.02M | $125.70M | $82.54M | $54.26M |
| Total assets | $734.73M | $655.68M | $175.55M | $131.44M | $83.75M | $54.55M |
| Current liabilities | $53.45M | $25.37M | $22.30M | $25.60M | $7.69M | $2.41M |
| Total debt | $74.84M | $50.69M | $49.88M | $24.81M | $4.92M | $0 |
| Total liabilities | $130.21M | $78.53M | $73.86M | $54.53M | $14.16M | $4.33M |
| Shareholders' equity | $604.52M | $577.15M | $101.69M | $76.91M | $69.59M | -$89.35M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$241.10M | -$134.68M | -$92.18M | -$67.60M | -$23.71M | -$34.81M |
| Capital expenditures | $630.0K | $972.0K | $63.0K | $62.0K | $0 | $99.0K |
| Free cash flow | -$241.73M | -$135.65M | -$92.24M | -$67.66M | -$23.71M | -$34.91M |
| Investing cash flow | $194.29M | -$425.03M | -$39.43M | -$70.55M | -$4.20M | -$42.0K |
| Financing cash flow | $308.90M | $606.67M | $133.54M | $101.93M | $53.88M | $85.29M |
| Share repurchases | $0 | $13.0K | $0 | - | - | - |
| Stock-based compensation | $37.93M | $20.80M | $11.49M | $8.89M | $3.01M | $331.0K |
| Depreciation and amortization | $468.0K | $105.0K | $21.0K | -$846.0K | $176.0K | $251.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Return on equity | -49.6% | -26.4% | -94.4% | -115.8% | -46.9% | - |
| Return on assets | -40.8% | -23.2% | -54.7% | -67.8% | -38.9% | -97.9% |
| Current ratio | 13.64 | 25.67 | 7.71 | 4.91 | 10.73 | 22.55 |
| Debt to equity | 0.12 | 0.09 | 0.49 | 0.32 | 0.07 | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.28M | - | - | - | $0 | - | - | - | - | - | - | - |
| Cost of revenue | $3.30M | - | - | - | $0 | - | - | - | - | - | - | - |
| Gross profit | $6.98M | - | - | - | $0 | - | - | - | - | - | - | - |
| Research and development | $41.25M | $60.08M | $86.01M | $59.31M | $56.47M | $58.20M | $41.28M | $33.35M | $40.31M | $29.31M | $23.20M | $20.79M |
| Selling, general and admin | $61.43M | $52.41M | $39.12M | $34.90M | $27.46M | $21.95M | $15.92M | $15.57M | $9.49M | $8.03M | $7.91M | $6.24M |
| Operating income | -$95.70M | -$112.49M | -$125.13M | -$94.21M | -$83.93M | -$80.14M | -$57.19M | -$48.91M | -$49.80M | -$37.34M | -$31.11M | -$27.03M |
| Interest expense | $1.87M | $1.85M | $1.82M | $1.90M | $1.96M | $1.87M | $1.79M | $1.87M | $1.94M | $1.91M | $1.91M | $1.06M |
| Net income | -$93.71M | -$109.47M | -$121.03M | -$91.10M | -$80.29M | -$76.53M | -$51.69M | -$43.42M | -$46.63M | -$33.71M | -$28.38M | -$25.66M |
| EPS, basic | -$1.30 | -$1.52 | -$1.69 | -$1.39 | -$1.26 | -$1.20 | -$0.81 | -$0.72 | -$0.85 | -$0.62 | -$0.56 | -$0.54 |
| EPS, diluted | -$1.30 | -$1.52 | -$1.69 | -$1.39 | -$1.26 | -$1.20 | -$0.81 | -$0.72 | -$0.85 | -$0.62 | -$0.56 | -$0.54 |
| Diluted shares | 72.1M | 71.8M | 71.5M | - | 63.8M | 63.8M | 63.7M | - | 54.9M | 54.7M | 51.0M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $55.32M | $48.88M | $114.35M | $354.73M | $57.77M | $49.12M | $55.09M | $92.65M | $27.26M | $25.09M | $69.11M | $45.68M |
| Short-term investments | $328.72M | $450.29M | $482.41M | $359.86M | $439.62M | $507.71M | $534.74M | $548.21M | $326.05M | $359.30M | $334.56M | $115.03M |
| Receivables | $11.98M | - | - | $0 | - | - | - | - | - | - | - | - |
| Inventory | $7.08M | - | - | $0 | - | - | - | - | - | - | - | - |
| Current assets | $441.29M | $527.49M | $615.80M | $728.88M | $511.31M | $571.35M | $606.08M | $651.22M | $364.13M | $394.75M | $416.37M | $172.02M |
| Total assets | $465.75M | $532.98M | $621.74M | $734.73M | $517.50M | $578.53M | $610.17M | $655.68M | $368.56M | $397.29M | $419.36M | $175.55M |
| Current liabilities | $55.77M | $48.32M | $45.15M | $53.45M | $41.88M | $33.55M | $21.89M | $25.37M | $26.46M | $18.42M | $14.54M | $22.30M |
| Total debt | $75.43M | $75.23M | $75.03M | $74.84M | $74.65M | $74.46M | $50.91M | $50.69M | $50.47M | $50.26M | $50.07M | $49.88M |
| Total liabilities | $132.57M | $125.23M | $122.04M | $130.21M | $118.62M | $110.25M | $75.17M | $78.53M | $79.50M | $69.42M | $65.81M | $73.86M |
| Shareholders' equity | $333.19M | $407.76M | $499.70M | $604.52M | $398.88M | $468.28M | $535.00M | $577.15M | $289.06M | $327.87M | $353.54M | $101.69M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$99.18M | -$100.25M | -$106.50M | -$69.99M | -$61.91M | -$54.80M | -$54.41M | -$39.18M | -$36.88M | -$24.78M | -$33.83M | -$25.14M |
| Capital expenditures | $0 | $0 | $23.0K | $102.0K | $133.0K | $208.0K | $187.0K | $645.0K | $238.0K | $89.0K | $0 | $63.0K |
| Free cash flow | -$99.18M | -$100.25M | -$106.52M | -$70.10M | -$62.04M | -$55.01M | -$54.59M | -$39.83M | -$37.12M | -$24.87M | -$33.83M | -$25.21M |
| Investing cash flow | $101.91M | $32.86M | -$137.82M | $80.66M | $69.76M | $28.54M | $15.32M | -$221.38M | $38.32M | -$22.68M | -$219.29M | $18.56M |
| Financing cash flow | $3.71M | $1.92M | $3.94M | $286.28M | $797.0K | $20.29M | $1.53M | $325.95M | $739.0K | $3.44M | $276.54M | $24.83M |
| Share repurchases | - | - | - | $0 | - | - | - | $0 | - | - | - | $0 |
| Stock-based compensation | $15.73M | $15.86M | $13.21M | $10.96M | $9.74M | $9.47M | $7.74M | $6.22M | $5.59M | $4.87M | $4.12M | $3.22M |
| Depreciation and amortization | $823.0K | $132.0K | $140.0K | $135.0K | $129.0K | $119.0K | $85.0K | $55.0K | $24.0K | $15.0K | $11.0K | $4.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 67.9% | - | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -931.2% | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | -911.9% | - | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | -965.0% | - | - | - | - | - | - | - | - | - | - | - |
| Current ratio | 7.91 | 10.92 | 13.64 | 13.64 | 12.21 | 17.03 | 27.68 | 25.67 | 13.76 | 21.43 | 28.63 | 7.71 |
| Debt to equity | 0.23 | 0.18 | 0.15 | 0.12 | 0.19 | 0.16 | 0.10 | 0.09 | 0.17 | 0.15 | 0.14 | 0.49 |
Source: XBRL data Vera Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
VERA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| VERA | - | - | -$415.31M | - | $2.15B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
VERA FAQ
6 questionsIs VERA profitable?
No. Vera Therapeutics Inc. reported a net loss of $415.31M for the twelve months ended Sep 30, 2026.How much cash and debt does VERA have?
Vera Therapeutics Inc. reported $55.32M in cash and cash equivalents and $75.43M of debt on its most recent balance sheet in SEC filings.What is VERA free cash flow?
Vera Therapeutics Inc. generated -$376.05M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$375.92M less capital expenditures.What is VERA earnings per share?
Diluted earnings per share were -$5.90 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did VERA last report financial results?
The latest statements here come from Vera Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this VERA financial data come from?
Quantisnow builds these statements from the structured XBRL data Vera Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.